Aurinia Pharmaceuticals/$AUPH
Aurinia Pharmaceuticals shares are trading higher after the company reaffirmed its FY25 guidance and reported a 25% increase in Lupkynis net product revenues.
1 hour ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Ticker
$AUPH
Sector
Primary listing
Industry
Biotechnology
Headquarters
Edmonton, Canada
Employees
130
ISIN
CA05156V1022
Website
AUPH Metrics
BasicAdvanced
$1.1B
31.54
$0.27
1.17
-
Price and volume
Market cap
$1.1B
Beta
1.17
52-week high
$9.98
52-week low
$5.20
Average daily volume
1.5M
Financial strength
Current ratio
5.932
Quick ratio
5.162
Long term debt to equity
17.809
Total debt to equity
22.248
Interest coverage (TTM)
9.19%
Profitability
EBITDA (TTM)
61.923
Gross margin (TTM)
79.76%
Net profit margin (TTM)
16.11%
Operating margin (TTM)
17.17%
Effective tax rate (TTM)
4.69%
Revenue per employee (TTM)
$1,900,000
Management effectiveness
Return on assets (TTM)
5.20%
Return on equity (TTM)
11.23%
Valuation
Price to earnings (TTM)
31.536
Price to revenue (TTM)
4.81
Price to book
3.3
Price to tangible book (TTM)
3.34
Price to free cash flow (TTM)
18.587
Free cash flow yield (TTM)
5.38%
Free cash flow per share (TTM)
45.14%
Growth
Revenue change (TTM)
29.20%
Earnings per share change (TTM)
-161.06%
3-year revenue growth (CAGR)
55.07%
10-year revenue growth (CAGR)
97.56%
3-year earnings per share growth (CAGR)
-40.61%
10-year earnings per share growth (CAGR)
-9.69%
What the Analysts think about AUPH
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
Bulls say / Bears say
Aurinia Pharmaceuticals reported strong financial results for Q4 and full-year 2024, with Q4 total revenue reaching $59.9 million (up 33% YoY) and net income of $1.4 million, compared to a loss of $26.9 million in Q4 2023. (stocktitan.net)
The company achieved a 36% year-over-year increase in LUPKYNIS net product sales, reaching $57.6 million in Q4 2024, indicating strong market adoption of its flagship product. (stocktitan.net)
Aurinia initiated a Phase 1 study of AUR200, a dual inhibitor for autoimmune diseases, with initial results expected in Q2 2025, potentially expanding its product pipeline. (stocktitan.net)
Analysts have lowered the consensus estimate for Aurinia's 2025 earnings from 55 cents per share to 47 cents per share over the past 60 days, indicating potential concerns about future profitability. (nasdaq.com)
Despite positive financial results, Aurinia's stock experienced a 5.03% decline following the Q4 2024 earnings report, suggesting investor skepticism or profit-taking. (stocktitan.net)
The company's stock has a beta of 1.24, indicating higher volatility compared to the market, which may pose risks for conservative investors. (tickerreport.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AUPH Financial Performance
Revenues and expenses
AUPH Earnings Performance
Company profitability
AUPH News
AllArticlesVideos
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Business Wire·2 weeks ago
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
Business Wire·2 weeks ago
Aurinia shares rise ahead of key autoimmune therapy data
Proactive Investors·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $1.1B as of July 10, 2025.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 31.54 as of July 10, 2025.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.